Singla, Daisy R.
de Oliveira, Claire
Murphy, Sean M.
Patel, Vikram
Charlebois, Jaime
Davis, Wendy N.
Dennis, Cindy-Lee
Kim, J. Jo
Kurdyak, Paul
Lawson, Andrea
Meltzer-Brody, Samantha
Mulsant, Benoit H.
Schoueri-Mychasiw, Nour
Silver, Richard K.
Tschritter, Dana
Vigod, Simone N.
Byford, Sarah
Funding for this research was provided by:
New Frontiers in Research Fund/Fonds Nouvelles Frontières en recherche (NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557, NFRF-2022-00557)
Article History
Received: 23 October 2023
Accepted: 27 October 2023
First Online: 8 November 2023
Declarations
:
: The current economic evaluation has received ethical approval via its parent study, The SUMMIT Trial:Ethical approvals were obtained from the Institutional Review Board of Clinical Trials Ontario Research Ethics Board [1895], University of North Carolina Biomedical Institutional Review Board [19–1786] and NorthShore University HealthSystem Institutional Review Board [EH18–129]. Informed consent was obtained from all study participants.
: Not applicable.
: The authors declare no competing interests.